Skip to main
KIDS
KIDS logo

OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics (KIDS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

OrthoPediatrics Corp demonstrated a positive financial trajectory with a 50 basis points year-over-year increase in gross margin, attributed to lower international set sales and 7D placements, while the adjusted EBITDA margin rose by 280 basis points. The Trauma & Deformity sales exhibiting a growth of 17.3% to $44.1 million, and strong performance in OPSB with over 20% growth in 3Q25, reflect the firm's solid positioning in the pediatric orthopedic market. Additionally, management's outlook suggests that as revenue continues to grow, improvements in operating leverage and cash flow are anticipated, further supported by new product introductions that may enhance margins.

Bears say

OrthoPediatrics Corp is experiencing a concerning slowdown in revenue growth, evidenced by a decline from 15.7% in Q2 to 12.2% in Q3 of 2025, which raises concerns about the company's ability to maintain momentum in a competitive market. Additionally, the company's guidance for FY25 has been lowered to $233.5M-$234.5M, indicating potential challenges in achieving anticipated financial performance, particularly as cash burn exceeds expectations. Bear case scenarios suggest that issues such as declining productivity among distributors and disappointing sales from new products could further exacerbate margin pressures and cash flow constraints.

OrthoPediatrics (KIDS) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OrthoPediatrics (KIDS) Forecast

Analysts have given OrthoPediatrics (KIDS) a Buy based on their latest research and market trends.

According to 8 analysts, OrthoPediatrics (KIDS) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OrthoPediatrics (KIDS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.